Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3764283 | 0.81 | ALDH1A1 (0.62) | NPC1RAB9AALDH1A1POLBKMT2A | |
| SCHEMBL14028404 | 0.74 | RAB9A (1.00) | NPC1RAB9AALDH1A1POLBKMT2A | |
| SCHEMBL21447625 | 0.73 | KMT2A (0.51) | NPC1RAB9AALDH1A1POLBKMT2A | |
| SCHEMBL859147 | 0.72 | — | — | |
| SCHEMBL25239515 | 0.71 | — | — | |
| SCHEMBL3763823 | 0.71 | — | — | |
| SCHEMBL13059104 | 0.71 | — | — | |
| SCHEMBL15474117 | 0.70 | — | — | |
| SCHEMBL10288448 | 0.69 | CYP2C19 (0.44) | NPC1RAB9AALDH1A1POLBKMT2A | |
| SCHEMBL2823812 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62030764-A | — | — | None | — | — | JP | disclosed |
| JP-62030766-A | — | — | None | — | — | JP | disclosed |
| JP-62030768-A | — | — | None | — | — | JP | disclosed |
| JP-62030767-A | — | — | None | — | — | JP | disclosed |
| JP-62030765-A | — | — | None | — | — | JP | disclosed |
| JP-62030777-A | — | — | None | — | — | JP | disclosed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | disclosed |
| JP-S6230768-A | IMIDAZOLE DERIVATIVE | TAISHO PHARMACEUT CO LTD | 1987-02-09 | — | — | JP | disclosed |
| JP-S6230767-A | IMIDAZOLE DERIVATIVE | TAISHO PHARMACEUT CO LTD | 1987-02-09 | — | — | JP | disclosed |
| JP-S6230764-A | IMIDAZOLE DERIVATIVE | TAISHO PHARMACEUT CO LTD | 1987-02-09 | — | — | JP | disclosed |
| JP-S6230766-A | IMIDAZOLE DERIVATIVE | TAISHO PHARMACEUT CO LTD | 1987-02-09 | — | — | JP | disclosed |
| JP-S6230765-A | IMIDAZOLE DERIVATIVE | TAISHO PHARMACEUT CO LTD | 1987-02-09 | — | — | JP | disclosed |
| JP-S6230777-A | IMIDAZOLE DERIVATIVE | TAISHO PHARMACEUT CO LTD | 1987-02-09 | — | — | JP | disclosed |
| JP-S06230777-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053931-A1 | Azaindoles | CDKN1A, CDK7, CDK2 | NPC1 2780/4885RAB9A 2089/4885ALDH1A1 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.